The Experts below are selected from a list of 2106 Experts worldwide ranked by ideXlab platform

Stephen D. Marks - One of the best experts on this subject based on the ideXlab platform.

  • Maximising living donation with paediatric Blood-Group-incompatible renal transplantation
    Pediatric Nephrology, 2013
    Co-Authors: Nizam Mamode, Stephen D. Marks
    Abstract:

    Long-term outcomes for paediatric renal transplant recipients have improved over the last 20 years, with better patient and renal allograft survival. As paediatric renal transplantation programmes have increased over this timeframe, living donation has become the favoured modality for renal replacement therapy and is advocated pre-emptively in as many cases as possible. However, one of the main barriers historically to living donation has been ABO Blood-Group Incompatibility, with the result that patients were listed to be on call for a deceased donor renal transplant. The clinical scenario has now changed so that donors and recipients for renal transplantation can be worked up and listed for paired exchange and/or living-related ABO Blood-Group-incompatible renal transplantation (ABOi). There is extensive data in adult practice, and increasing evidence in paediatric practice that the short- and medium-term outcomes for both patient and renal allograft survival for ABOi is equivalent to that of Blood-Group-compatible renal transplantation.

Kazuaki Yokoyama - One of the best experts on this subject based on the ideXlab platform.

  • effect of abo Blood Group Incompatibility on the outcome of single unit cord Blood transplantation after myeloablative conditioning
    Biology of Blood and Marrow Transplantation, 2014
    Co-Authors: Takaaki Konuma, Seiko Kato, Maki Oiwamonna, Yasuhiro Ebihara, Shinji Mochizuki, Koichiro Yuji, Toyotaka Kawamata, Norihide Jo, Nobuhiro Ohno, Kazuaki Yokoyama
    Abstract:

    Abstract ABO Blood Group Incompatibility between donor and recipient has been associated with poor transplant outcomes in allogeneic hematopoietic stem cell transplantation. However, its effect on the outcome of cord Blood transplantation (CBT) has yet to be clarified. We retrospectively analyzed 191 adult patients who received single-unit CBT after myeloablative conditioning for malignant disease in our institute. Major mismatch showed a significantly lower incidence of platelet engraftment compared with ABO match as a reference (hazard ratio, .57; P  = .01). Nevertheless, there was no increase in graft-versus-host disease, transplant-related mortality, and overall mortality after ABO-incompatible CBT. These data suggested that donor–recipient ABO Incompatibility does not have a significant impact on outcome after myeloablative CBT for hematological malignancies.

Nizam Mamode - One of the best experts on this subject based on the ideXlab platform.

  • Maximising living donation with paediatric Blood-Group-incompatible renal transplantation
    Pediatric Nephrology, 2013
    Co-Authors: Nizam Mamode, Stephen D. Marks
    Abstract:

    Long-term outcomes for paediatric renal transplant recipients have improved over the last 20 years, with better patient and renal allograft survival. As paediatric renal transplantation programmes have increased over this timeframe, living donation has become the favoured modality for renal replacement therapy and is advocated pre-emptively in as many cases as possible. However, one of the main barriers historically to living donation has been ABO Blood-Group Incompatibility, with the result that patients were listed to be on call for a deceased donor renal transplant. The clinical scenario has now changed so that donors and recipients for renal transplantation can be worked up and listed for paired exchange and/or living-related ABO Blood-Group-incompatible renal transplantation (ABOi). There is extensive data in adult practice, and increasing evidence in paediatric practice that the short- and medium-term outcomes for both patient and renal allograft survival for ABOi is equivalent to that of Blood-Group-compatible renal transplantation.

Takaaki Konuma - One of the best experts on this subject based on the ideXlab platform.

  • effect of abo Blood Group Incompatibility on the outcome of single unit cord Blood transplantation after myeloablative conditioning
    Biology of Blood and Marrow Transplantation, 2014
    Co-Authors: Takaaki Konuma, Seiko Kato, Maki Oiwamonna, Yasuhiro Ebihara, Shinji Mochizuki, Koichiro Yuji, Toyotaka Kawamata, Norihide Jo, Nobuhiro Ohno, Kazuaki Yokoyama
    Abstract:

    Abstract ABO Blood Group Incompatibility between donor and recipient has been associated with poor transplant outcomes in allogeneic hematopoietic stem cell transplantation. However, its effect on the outcome of cord Blood transplantation (CBT) has yet to be clarified. We retrospectively analyzed 191 adult patients who received single-unit CBT after myeloablative conditioning for malignant disease in our institute. Major mismatch showed a significantly lower incidence of platelet engraftment compared with ABO match as a reference (hazard ratio, .57; P  = .01). Nevertheless, there was no increase in graft-versus-host disease, transplant-related mortality, and overall mortality after ABO-incompatible CBT. These data suggested that donor–recipient ABO Incompatibility does not have a significant impact on outcome after myeloablative CBT for hematological malignancies.

Norihide Jo - One of the best experts on this subject based on the ideXlab platform.

  • effect of abo Blood Group Incompatibility on the outcome of single unit cord Blood transplantation after myeloablative conditioning
    Biology of Blood and Marrow Transplantation, 2014
    Co-Authors: Takaaki Konuma, Seiko Kato, Maki Oiwamonna, Yasuhiro Ebihara, Shinji Mochizuki, Koichiro Yuji, Toyotaka Kawamata, Norihide Jo, Nobuhiro Ohno, Kazuaki Yokoyama
    Abstract:

    Abstract ABO Blood Group Incompatibility between donor and recipient has been associated with poor transplant outcomes in allogeneic hematopoietic stem cell transplantation. However, its effect on the outcome of cord Blood transplantation (CBT) has yet to be clarified. We retrospectively analyzed 191 adult patients who received single-unit CBT after myeloablative conditioning for malignant disease in our institute. Major mismatch showed a significantly lower incidence of platelet engraftment compared with ABO match as a reference (hazard ratio, .57; P  = .01). Nevertheless, there was no increase in graft-versus-host disease, transplant-related mortality, and overall mortality after ABO-incompatible CBT. These data suggested that donor–recipient ABO Incompatibility does not have a significant impact on outcome after myeloablative CBT for hematological malignancies.